Atsushi Manabe
Atsushi Manabe, MD, PhD is an expert in Hematology at St. Luke's International Hospital (Japan). As of October 2026, ScienceLeadR ranks Atsushi Manabe in the top 1% of experts worldwide for Leukemia and Lymphoproliferative Disorders. Atsushi Manabe has authored 532 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 1,585 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Pediatrics - Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1993 - 2026
Number : 532
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study. PMID 42874021 — safety, neoplasms, thyroid gland, drug-related side effects and adverse reactions, adolescent, thyroid neoplasms, therapeutics, medical oncology | J Clin Oncol Top journal | 2026 | 0 |
| Trametinib Plus Azacitidine as Bridging Therapy to Hematopoietic Stem Cell Transplantation in an Infant With PTPN11-Mutated Juvenile Myelomonocytic Leukemia. PMID 42873069 — cells, leukemia, myelomonocytic, juvenile, microscopy, electron, scanning transmission, hematopoietic stem cell transplantation, neoplasms, leukemia, stem cells, azacitidine, therapeutics, cell transplantation, stem cell transplantation, hematopoietic stem cells, transplantation, infant | Pediatr Blood Cancer | 2026 | 0 |
| Clinical features and prognosis of EGPA-associated peripheral neuropathy: a multicentre REVEAL cohort study. PMID 42832112 — peripheral nervous system diseases, serum, cohort studies, eosinophils, neurosurgery, neurology, prognosis | J Neurol | 2026 | 0 |
| Reduced severe infection risk with avacopan in ANCA-associated vasculitis: a multicentre REVEAL cohort with time-varying exposure modelling. PMID 42757695 — glucocorticoids, vasculitis, prednisolone, propensity score, rheumatic diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, therapeutics, infections | Rheumatology (Oxford) | 2026 | 0 |
| Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings-international expert consensus. PMID 42578884 — precursor cell lymphoblastic leukemia-lymphoma, safety, asparaginase, neoplasms, leukemia, therapeutics | Cancer | 2026 | 0 |
Clinical Studies 2
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| ONC201 in H3 K27M mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) NCT05580562 — radiotherapy, glioma, thalamus, capsules, histones, body weight, therapeutics | Phase 3 | Recruiting | 2023 |
LeadR Networks
Main global connection map